The Therapeutic Goods Administration (TGA), a division of the Department of Health, is planning to publish a Request for Tender in October 2017 for the establishment of a new Therapeutic Goods Evaluation Panel to provide medical and scientific evaluation services. The Panel will operate from July 2018, and will replace the current Therapeutic Goods Assessment and Advisory Services Panel. The Therapeutic Goods Evaluation Panel is expected to deliver evaluation services for technical streams as follows: 1. Clinical medicines and clinical technologies 2. Nonclinical (pharmacology/toxicology) sciences 3. Quality of pharmaceutical therapeutic goods (synthetic pharmaceuticals, biological sciences) 4. Biostatistics 5. Epidemiology or pharmacoepidemiology 6. Population pharmacokinetic analysis 7. Emerging technologies such as nanotechnology, gene technology and cell therapy 8. Clinical trial and research methodologies Industry briefings in selected major cities will be held in November 2017.